Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

por Locatelli, Franco, Zugmaier, Gerhard, Mergen, Noemi, Bader, Peter, Jeha, Sima, Schlegel, Paul-Gerhardt, Bourquin, Jean-Pierre, Handgretinger, Rupert, Brethon, Benoit, Rossig, Claudia, Chen-Santel, Christiane
Publicado 2020

Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

por Locatelli, Franco, Zugmaier, Gerhard, Mergen, Noemi, Bader, Peter, Jeha, Sima, Schlegel, Paul-Gerhardt, Bourquin, Jean-Pierre, Handgretinger, Rupert, Brethon, Benoit, Rossig, Claudia, Chen-Santel, Christiane
Publicado 2021

Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

por Locatelli, Franco, Zugmaier, Gerhard, Mergen, Noemi, Bader, Peter, Jeha, Sima, Schlegel, Paul-Gerhardt, Bourquin, Jean-Pierre, Handgretinger, Rupert, Brethon, Benoit, Rossig, Claudia, Chen-Santel, Christiane
Publicado 2021

Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis

por Locatelli, Franco, Zugmaier, Gerhard, Mergen, Noemi, Bader, Peter, Jeha, Sima, Schlegel, Paul-Gerhardt, Bourquin, Jean-Pierre, Handgretinger, Rupert, Brethon, Benoit, Rössig, Claudia, Kormany, William N., Viswagnachar, Puneeth, Chen-Santel, Christiane
Publicado 2022